You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

McKinsey
Boehringer Ingelheim
Medtronic
Johnson and Johnson
Harvard Business School
Dow

Last Updated: September 26, 2020

DrugPatentWatch Database Preview

Patent: 9,376,452

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 9,376,452
Title:Rab7 GTPase inhibitors and related methods of treatment
Abstract: This invention relates to compounds and their use as inhibitors or activators of Rab7 GTPase to treat or prevent the onset of Rab 7 GTPase-associated disorders such as neuropathies, cancer, metabolic diseases of bone and lipid storage. The invention is also applicable to infectious diseases where Rab7 is inactivated or its protein-protein interactions are modulated to facilitate intracellular survival of pathogens. The compound described acts as a competitive inhibitor of nucleotide binding and as such also has utility as a scaffold for targeting other small GTPases. In one aspect, methods of treatment of the invention are used to treat or prevent the onset of hereditary sensory neuropathies such as Charcot-Marie-Tooth type 2B disease. Related pharmaceutical compositions, assays, and drug screens are also provided.
Inventor(s): Wandinger-Ness; Angela (Albuquerque, NM), Sklar; Larry (Albuquerque, NM), Agola; Jacob (Albuquerque, NM), Surviladze; Zurab (Albuquerque, NM), Aube; Jeffrey (Lawrence, KS), Golden; Jennifer (Olathe, KS), Schroeder; Chad E. (Lawrence, KS), Simpson; Denise S. (Lawrence, KS)
Assignee: ST. UNM (Albuquerque, NM)
Application Number:14/278,468
Patent Claims:see list of patent claims

Details for Patent 9,376,452

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Imclone ERBITUX cetuximab VIAL; INTRAVENOUS 125084 001 2004-06-18   Start Trial ST. UNM (Albuquerque, NM) 2031-03-02 RX Orphan search
Genentech AVASTIN bevacizumab VIAL; INTRAVENOUS 125085 001 2004-02-26   Start Trial ST. UNM (Albuquerque, NM) 2031-03-02 RX Orphan search
Genentech AVASTIN bevacizumab VIAL; INTRAVENOUS 125085 002 2004-02-26   Start Trial ST. UNM (Albuquerque, NM) 2031-03-02 RX Orphan search
Amgen VECTIBIX panitumumab INJECTABLE; IV (INFUSION) 125147 001 2006-09-27   Start Trial ST. UNM (Albuquerque, NM) 2031-03-02 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
Boehringer Ingelheim
Johnson and Johnson
Harvard Business School
McKinsey
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.